Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

370 Reports from FirstWord

   
  • Breast Cancer: KOL Insight [2017]

    ...face the threat of biosimilar trastuzumab in the coming years; KOLs weigh in on how biosimilar trastuzumab may be accepted by physicians and patients, its potential usage in different settings, as well as its chances ... Read More

  • Charting MSL Activity and Performance (2017)

    ...(MSL) professionals in the US and EU5 which reveals the changing face of MSL activity and the key engagement strategies and performance metrics that are being employed today. Building on the ground breaking 2015 Survey, ... Read More

  • Market Access Impact (US) [Haemophilia A]

    ...8 brands we surveyed have nearly equal market share. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage. Learn how 7 barriers ... Read More

  • Market Access Impact (EU5) [Haemophilia A]

    ...for several of the brands we surveyed are very close. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage. Learn how 7 ... Read More

  • Market Access Impact (EU5) [CLL]

    ...is clearly popular and others are playing ‘catch-up’ on the market share stakes – but what difference would it make if the landscape shifted and non-clinical constraints such as cost, availability, administrative restrictions, institutional guidelines, ... Read More

  • Biomarkers and Companion Diagnostics - Payer views

    ...to realising the personalised medicines agenda. They support clinician decision making and are cost efficient for payers. But payers identify challenges around evidence of clinical utility, inconsistent practice between - and within – countries, and ... Read More

  • The Future of Biosimilars in Europe: Mapping critical uncertainties and the impact of future events

    ...eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next frontier in the European biosimilars market, but warn that they may not achieve widespread uptake unless stakeholders can put doctors’ and patients’ ... Read More

  • Medical Affairs Reputations (US) [MS]

    ...to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but one in five physicians suggest that medical affairs teams could do better at providing specific information. Is ‘satisfactory’ ... Read More

  • CAR-T Disease Outlook [2017]

    ...leukaemia (ALL) and non-Hodgkin lymphoma (NHL) with high unmet needs. How will the impressive efficacy and safety of these therapies pan out in the long-term? Key opinion leaders (KOLs) explore the clinical challenges and opportunities ... Read More

  • Market Access Impact (US) [CLL]

    ...drug is clearly popular and others are playing ‘catch-up’ on the market share stakes – but what difference would it make if the landscape shifted and non-clinical constraints such as cost, availability, administrative restrictions, institutional ... Read More

  • Market Access Impact (EU5) [Growth Hormone Deficiency]

    ...countries. Most brands lose market share because of them, but for some brands, perception may be an even bigger problem. As many as 16% of the doctors we surveyed either wouldn’t prescribe these brands, or ... Read More

  • NPS+ (EU5) [Melanoma]

    ...Can either one pull ahead? It won’t be easy. According to our survey, doctors recommend these brands for largely the same reasons, and may even see them as interchangeable. Find out how doctors rated your ... Read More

  • Medical Affairs Reputations (EU5) [MS]

    ...to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but almost a quarter of physicians suggest that medical affairs teams could improve their attitude and practice. Is ‘satisfactory’ ... Read More

  • Market Access Impact (US) [Growth Hormone Deficiency]

    ...and most brands lose market share because of them. According to the endocrinologists we surveyed, that’s a problem with no single solution; many of them experience as many as 3 different barriers with any given ... Read More

  • NPS+ (US) [Melanoma]

    ...US-based medical oncologists and dermato-oncologists are optimistic about these two drugs, but haven’t had many opportunities to prescribe them. Meanwhile, the top 2 brands are comfortably ahead thanks mainly to widespread perceptions about their clinical ... Read More

  • NASH: KOL Insight [2017]

    ...next five years? Allergan/Tobira’s cenicriviroc and Gilead’s selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept’s obeticholic acid and Genfit’s elafibranor. How important are improvements in fibrosis and ... Read More

  • Medical Affairs in Orphan Drugs

    ...the physician and patient populations are so much smaller – and the value of individual relationships is consequently higher as a result. But some players are achieving success with high-performing medical affairs teams and sophisticated ... Read More

  • COPD [2017]

    ...Obstructive Lung Disease (GOLD) recommend LABA/LAMAs as first line therapy in symptomatic patients regardless of exacerbation risk, and KOLs agree. LABA/LAMA marketing companies set to benefit include AstraZeneca, Boehringer Ingelheim, GSK and Novartis, but which ... Read More

  • Market Access Impact (US) [RCC]

    ...are preventing oncologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand? ... Read More

  • Market Access Impact (EU5) [RCC]

    ...EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, ... Read More

  • Prostate Cancer [2016]: Bulletin #2

    ...[olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250 Phase III study that was initiated in ... Read More

  • Real World Data -- Meeting payer needs

    ...Payers with stretched budgets are still struggling to make the case for ‘big ticket’ drugs. Whereas pharma is keen to prove that higher cost drugs are justified and will ultimately save money. But are payers ... Read More

  • How Payers Want to Work With Pharma

    ...approach to payer negotiations getting your message across? Too often pharma fails to provide the data and contracting innovation that will unlock the door to a deal. It can be better. Report Overview In How ... Read More

  • Ovarian Cancer [2017]

    ...Co.’s Zejula. How will AstraZeneca’s Lynparza fare in the rapidly growing PARP inhibitor market and will the newer therapies in this class prove their worth? Furthermore, a multitude of novel combinations are being evaluated in ... Read More

  • NPS+ (US) [Asthma/COPD]

    ...abundance of choice impacting brand loyalty? What do physicians think today about the leading brands? And are they talking positively or negatively about each to their peers? Brand marketers can find out everything they need ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook